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Parallels between Cancer and Infectious Disease
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Infectious diseases and cancer have multiple 
similarities. Both infectious organisms and can-
cer cells express many proteins that are recog-
nizable by host T cells,1 and both elicit T-cell–
mediated inflammation. An essential aspect of 
T-cell homeostasis is that the responses of these 
cells must eventually diminish to avoid toxicity 
from excessive T-cell proliferation and cytokine 
release. Unfortunately, this can lead to a loss of 
appropriate T-cell responses, especially in ad-
vanced cancer and chronic infections.
Scientists have identified many of the normal 
mechanisms in cancer and indolent infections 
that ordinarily limit T-cell responses. These 
findings have led to the development of agents 
that can overcome the limiting mechanisms to 
“unleash” or amplify ongoing T-cell responses 
under conditions of adaptive immune suppres-
sion.2 These agents are designed to alleviate or 
reverse such events as “T-cell exhaustion” 
brought about by inhibitory molecules (e.g., pro-
grammed cell death 1 [PD-1] and programmed 
cell death ligand 1 [PD-L1]), an increased num-
ber of myeloid-derived suppressor and T-regula-
tory cells, decreased expression of HLA-DR by 
antigen-presenting cells, and a shift from M1 
(killer) macrophages to M2 macrophages, which 
dampen the immune system by secreting antiin-
flammatory cytokines such as interleukin-10 
(Fig. 1). Many of the agents that can expand the 
T-cell response are being developed for cancer 
therapy.3 Similarly, agents that block immuno-
suppressive proteins or cytokines that suppress 
T-cell responses (e.g., antibodies that counter 
interleukin-10 and transforming growth factor β) 
are also being developed as potential drugs for 
treating cancer. Several of these agents are also 
likely to be efficacious in patients with chronic 
infectious diseases.
Why do cancer and many infectious disor-
ders induce similar immunologic responses? 
Persistent immune activation and inflammation 
play key roles. Chronic antigenic stimulation 
caused by damage-associated molecular pattern 
(DAMP) and pathogen-associated molecular pat-
tern (PAMP) molecules occurs in cancer and in-
fectious disorders, respectively. DAMPs and 
PAMPS bind to similar or, in some cases, identi-
cal toll-like receptors (TLRs) and NOD-like re-
ceptors (NLRs), which unlike most receptors are 
able to respond to a variety of conserved foreign 
Figure 1 (facing page). Immune Phenotypes of Cancer 
and Protracted Infection.
Tumor and pathogen antigens persistently activate  
T cells, which ultimately leads to T-cell exhaustion. 
Chronic release of damage-associated molecular pat-
tern (DAMP) molecules and pathogen-associated mo-
lecular pattern (PAMP) molecules occurs in cancer and 
infectious disorders, respectively, leading to activation 
of common signaling pathways mediated by toll-like re-
ceptors (TLRs) and NOD-like receptors (NLRs), which 
regulate immunity (see the Glossary). Protracted in-
flammation that is caused by reactive oxygen and ni-
trogen species also occurs in both disorders. Apoptotic 
tumor or immune cells are engulfed by phagocytic 
cells, which subsequently release immunosuppressive 
cytokines. Collectively, these processes lead to an 
 immunosuppressive environment with “exhausted”  
T cells expressing inhibitory molecules (e.g., pro-
grammed cell death 1 [PD-1] and programmed cell 
death ligand 1 [PD-L1]), increased numbers of T-regu-
latory cells and myeloid-derived suppressor cells, and 
a shift from type 1 helper T (Th1) cells to type 2 helper 
T (Th2) cells and from M1 to M2 macrophages. Tumor 
cells, vascular endothelial cells, myeloid-derived sup-
pressor cells, and infected parenchymal cells express 
PD-L1, which associates with the inhibitory receptor, 
PD-1, to induce the suppression of T cells and natural 
killer cells, thereby preventing the destruction of tu-
mors or pathogens. Red arrows represent the secretion 
of molecules with inhibitory function. PMN denotes 
polymorphonuclear leukocyte, and TGF-β transforming 
growth factor β.
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Common local stimuli
Persistent antigen exposure (activation of 
DAMPs and PAMPs)
Protracted inflammation (release of reactive 
oxygen species or reactive nitrogen species)
Recruitment of immune cells (PMNs, 
lymphocytes, and macrophages)
Release of immunosuppressive mediators 
(interleukin-10, TGF-β) by apoptotic cells
Common Immunosuppressive Mechanisms 
T-cell exhaustion, myeloid-derived 
suppressor cells, T-regulatory cells, and M2 
macrophages
Release of immunosuppressive mediators 
(interleukin-10, TGF-β) by apoptotic cells
Expression of inhibitory ligands on tumor or 
parenchymal cells
Immune checkpoints and reactive nitrogen 
species
Early Neoplasia Early Infection
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or host ligands. Binding of TLRs and NLRs leads 
to the activation of common signaling pathways 
that regulate immunity. DAMPs and PAMPs 
mediate and amplify inflammation, which re-
sults in the release of similar proinflammatory 
and antiinflammatory cytokines, increased levels 
of reactive oxygen and nitrogen species, tissue 
wasting, and increased apoptosis. The totality 
of these processes has detrimental effects on 
host protective and antitumor immunity.
In considering new experimental approaches, 
a central challenge is how to boost host immu-
nity without causing potential adverse effects 
associated with an overreactive immune system. 
Serious autoimmune disorders develop in some 
patients with cancer who have been treated with 
immune checkpoint inhibitors of PD-1 and cyto-
toxic T-lymphocyte antigen 4 (CTLA4) (see the 
Glossary). It is believed that such disorders re-
sult from the unleashing of ongoing or nascent 
autoimmune-like T-cell responses.3 Similarly, 
boosting immunity in patients with sepsis 
might worsen inflammation and organ injury in 
those who have not entered the immunosup-
pressive phase. Thus, identifying the right can-
didates for and timing of immunotherapy in pa-
tients with either cancer or persistent severe 
infection is essential.
In two recent studies, investigators made po-
tential advances in identifying appropriate pa-
tient populations.4,5 Using a model of chronic 
viral infection in mice, Crawford et al.4 analyzed 
immune effector cells at the level of the tran-
scriptome. They identified unique gene-expres-
sion patterns involving inhibitory receptors and 
transcription factors that are present in dys-
functional CD4+ and CD8+ T cells. These find-
ings provide a foundation for further develop-
ment of a quantitative nucleic acid–based 
method of identifying and targeting patient-spe-
cific immunologic defects.
Another method to gauge host immunity 
uses the patient as a “test tube.” Most healthy 
persons harbor numerous latent viruses (e.g., 
cytomegalovirus, herpes simplex virus type 1, 
and Epstein–Barr virus), which can reactivate, 
replicate, and enter the circulation during 
 impaired host immunity. De Vlaminck et al. 
performed serial sequencing of the virome in 
patients undergoing organ transplantation.5 
Results showed a correlation between the total 
viral load and the intensity and dose of medica-
tions used to suppress immunity and prevent 
organ rejection. They also observed a correla-
tion between the types of virus that were de-
tected and the intensity and dose of medica-
tions. Tapering of immunosuppressive drugs led 
to changes in specific viruses and a reduction in 
viral loads. If replicated, tests that quantitate 
the human virome may be useful in predicting 
immunocompetence in hospitalized patients.
A revolution in immunotherapy is under way 
in oncology, and its turbulence is beginning to 
affect the experimental treatment of infectious 
diseases. Granulocyte–macrophage colony-stim-
ulating factor (GM-CSF) is in clinical trials in-
volving patients with cancer and sepsis. Anti–
PD-1 and anti–PD-L1 drugs have been effective 
in several clinical trials to treat melanoma, 
non–small-cell lung cancer, and renal-cell can-
cer, and they are being tested in the treatment 
of human immunodeficiency virus infection. In-
terleukin-7, one of the most promising and 
broadly active immunomodulators, was effica-
cious in early trials involving pediatric patients 
with sarcoma and was found to reverse gut pa-
thology in patients with HIV infection or JC vi-
rus–induced progressive multifocal leukoen-
cephalopathy.6
What next? An experimental test of these ap-
proaches to treat sepsis could be considered. On 
a more general level, greater collaboration is re-
quired between oncologists, infectious-disease 
specialists, translational immunologists, and 
pharmaceutical companies in developing clini-
cally relevant tests that identify patient-specific 
Glossary
Programmed cell death 1 (PD-1): Inhibits T-cell function and can trigger ap-
optosis; is present on T-cells.
Programmed cell death ligand 1 (PD-L1): Binds to or activates the PD-1 re-
ceptor, which is present on antigen-presenting cells and, less frequently, 
on T cells.
Cytotoxic T-lymphocyte antigen 4 (CTLA4): Inhibits T-cell function and is 
present on T cells.
Granulocyte–macrophage colony-stimulating factor (GM-CSF): Stimulates 
the production of granulocytes and monocytes.
NOD-like receptor (NLR): Intracellular pattern-recognition receptor of PAMPs 
and DAMPs.
The New England Journal of Medicine 
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on August 16, 2014. For personal use only. No other uses without permission. 
 Copyright © 2014 Massachusetts Medical Society. All rights reserved. 
n engl j med 371;4 nejm.org july 24, 2014 383
defects in innate or adaptive immunity. The 
 recently announced and unprecedented collab-
oration among four major pharmaceutical 
companies in developing combination immuno-
therapeutic drugs for cancer7 underscores the 
perceived importance of immunotherapy and 
the recognition that teamwork is critical to suc-
cess. Rapid tests of the overall health of a pa-
tient’s immune system would enable clinicians 
to guide immunotherapy and follow its efficacy. 
Nucleic acid–based detection of mechanisms of 
immunosuppression and of reactivated latent vi-
ruses might identify candidates for immuno-
therapy and enable therapeutic monitoring.4,5 
Coordination of clinical trials with sharing of 
data and patient samples would expedite drug 
development. A change in clinical outcomes — 
in both cancer and infectious disease — will oc-
cur more quickly if investigators in these spe-
cialties pull together.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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